In vivo tau imaging: Obstacles and progress
In vivo tau imaging: Obstacles and progress
复制标题
体内 tau 成像：障碍与进展
DOI：
10.1016/j.jalz.2014.04.013
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
N. Okamura
中科院分区：
文献类型：
--
作者：
V. Villemagne;N. Okamura
过去十年的军事冲突突出表明，从战场返回的战斗人员的创伤性脑损伤问题日益严重。相当多的证据表明tau聚集体的积累及其在阿尔茨海默病等神经退行性疾病中被认为是一个风险因素，这导致了一项重大努力，即开发选择性tau配体，从而能够研究军事人员和平民中创伤性脑损伤和慢性创伤性脑病的生理病理基础。这些示踪剂将为人类大脑中tau的病理提供新的见解，促进对创伤性脑病和主要神经退行性痴呆的原因、诊断和治疗的研究，例如阿尔茨海默病和额颞叶变性的一些变体，tau在其中发挥作用。选择性tau成像领域必须克服几个障碍，其中一些与tau聚集的特性有关，另一些与放射性示踪剂设计有关。全世界的努力都集中在开发显像剂上，这种显像剂将允许在体内进行选择性的tau成像。这些示踪剂开发的最新进展使非侵入性评估tau病理在大脑中的程度成为可能，最终能够量化tau病理随时间的变化及其与认知表现、脑体积测量和其他生物标记物的关系，以及评估疗效和患者招募以进行抗tau治疗试验。
The military conflicts of the last decade have highlighted the growing problem of traumatic brain injury in combatants returning from the battlefield. The considerable evidence pointing at the accumulation of tau aggregates and its recognition as a risk factor in neurodegenerative conditions such as Alzheimer's disease have led to a major effort to develop selective tau ligands that would allow research into the physiopathologic underpinnings of traumatic brain injury and chronic traumatic encephalopathy in military personnel and the civilian population. These tracers will allow new insights into tau pathology in the human brain, facilitating research into causes, diagnosis, and treatment of traumatic encephalopathy and major neurodegenerative dementias, such as Alzheimer's disease and some variants of frontotemporal lobar degeneration, in which tau plays a role. The field of selective tau imaging has to overcome several obstacles, some of them associated with the idiosyncrasies of tau aggregation and others related to radiotracer design. A worldwide effort has focused on the development of imaging agents that will allow selective tau imaging in vivo. Recent progress in the development of these tracers is enabling the noninvasive assessment of the extent of tau pathology in the brain, eventually allowing the quantification of changes in tau pathology over time and its relation to cognitive performance, brain volumetrics, and other biomarkers, as well as assessment of efficacy and patient recruitment for antitau therapeutic trials.
登录
查看更多内容
影响因子：
9.9
作者：
R. Faber
通讯作者：
R. Faber
影响因子：
13.8
作者：
Pike VW
通讯作者：
Pike VW
DOI：
10.1073/pnas.0406361102
发表时间：
2005-01-04
影响因子：
11.1
作者：
Zhang, B;Maiti, A;Trojanowski, JQ
通讯作者：
Trojanowski, JQ
影响因子：
120.7
作者：
Näslund, J;Haroutunian, V;Buxbaum, JD
通讯作者：
Buxbaum, JD
影响因子：
7.3
作者：
Bolaender, Alexander;Kieser, Daniel;Schmidtt, Boris
通讯作者：
Schmidtt, Boris